Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2013 / Cilt: 23 - Sayı: 3

Küçük Hücreli Dışı Akciğer Karsinomlu Neoadjuvan Tedavi Alan ve Almayan Hastalarda Preoperatif PET-BT’nin Tanısal Performansının Karşılaştırılması: ‹ndüksiyon Tedavisi Preoperatif PET-BT Sonuçlarını Etkiliyor mu?

Comparison of Diagnostic Performance of Preoperative PET-CT for Patients with and without Neoadjuvant Therapy in Non-Small Cell Lung Cancer: Does Induction Therapy Affect the Preoperative PET-CT Results?

Pages
143–152
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

PET-CT appears to be beneficial for the assessment of patients those are planned to be treated surgically for lung cancer whether they have received induction therapy or not.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:PET-CT has been widely used for restaging after induction therapy in patients with non-small cell lung carcinoma.
📊
Key Findings & Data:There were 217 patients, 58 in neoadjuvant group and 159 in control (without preoperative induction therapy) group.
💡
Conclusion & Impact:PET-CT appears to be beneficial for the assessment of patients those are planned to be treated surgically for lung cancer whether they have received induction therapy or not.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

PET-CT has been widely used for restaging after induction therapy in patients with non-small cell lung carcinoma. We aimed to assess the role of preoperative PET-CT in patients receiving induction therapy and compare with those without induction therapy. Patients treated with surgery for non-small cell lung carcinoma were included. There were two subgroups according to the presence of preoperative induction therapy. The results of preoperative PET-CT in these two groups were compared. There were 217 patients, 58 in neoadjuvant group and 159 in control (without preoperative induction therapy) group. In N2 lymph nodes, the positive predictive value (PPV) was significantly higher in the neoadjuvant group than in the control group (p=0.01), where the negative predictive value (NPV) (p=0.0001) and accuracy (p=0.03) were significantly lower. In aorticopulmonary lymph nodes, the NPV was significantly higher in the control group (p=0.002). In lower N2 lymph nodes, the PPV was higher (p=0.007) and the NPV was lower (p=0.003) in the neoadjuvant group. In N1 lymph nodes, the specificity was found to be lower in the neoadjuvant group (p=0.01). The sensitivity, PPV and accuracy for mass was lower in the neoadjuvant group (p=0.002, p=0.0003, and p=0.001, respectively). The negative predictive value and accuracy of PET-CT were slightly decreased in patients with non-small cell lung carcinoma received induction therapy before surgical resection. PET-CT appears to be beneficial for the assessment of patients those are planned to be treated surgically for lung cancer whether they have received induction therapy or not.

Özet

PET-BT küçük hücreli dışı akciğer karsinomlu hastalarda indüksiyon tedavisi sonrası yeniden evrelemede yaygın olarak kullanılmaktadır. Preoperatif PET-BT’nin indüksiyon tedavisi alan hastalardaki rolünü araştırmayı ve tedavi almayanlar ile karşılaştırmayı amaçladık. Küçük hücreli dışı akciğer karsinomu nedeniyle cerrahi olarak tedavi edilen hastalar çalışmaya alındı. Preoperatif indüksiyon tedavisi varlığına göre iki subgrup oluşturuldu. Bu iki grup arasında preoperative PET-BT sonuçları karşılaştırıldı. Neoadjuvan grubunda 58 ve kontrol (preoperatif indüksiyon tedavisi almayan) grupta 159, toplam 217 hasta alındı. N2 lenf nodlarında, pozitif prediktif de- ğer (PPV) neoadjuvan grupta kontrol grubuna göre anlamlı şekilde yüksek (p= 0,01), negatif prediktif değer (NPV) (p= 0.0001) ve doğ- ruluk (p= 0.03) düşük idi. Aortikopulmoner lenf nodlarında, kontrol grubunda NPV anlamlı şekilde yüksek idi (p= 0.002). Alt N2 lenf nodlarında, neoadjuvan grubunda PPV yüksek (p= 0.007) ve NPV düşük (p= 0.003) idi. N1 lenf nodlarında, neoadjuvan grubunda spesifite düşük (p= 0.01) idi. Bu grupta kitle için sensitivite, PPV ve doğruluk düşük (p=0.002, p= 0.0003 ve p= 0.001) idi. Cerrahi rezeksiyon öncesi indüksiyon tedavisi alan küçük hücreli dışı akciğer karsinomlu hastalarda PET-BT’nin negatif prediktif de- ğeri ve doğruluğu hafif azalmaktadır. Cerrahi tedavi planlanan akciğer kanserli hastaların değerlendirilmesinde, indüksiyon tedavisi uygulanmış olsa da olmasa da PET-BT faydalı olmaktadır.

🔖

Cite This Article

GÜRSOY, S., ÜÇVET, A., ERBAYCU, A. E., YAMANSAVCI, E., KOPARAL, H., ÖZBİLEK, E., KAYA, S. O. (2013). Küçük Hücreli Dışı Akciğer Karsinomlu Neoadjuvan Tedavi Alan ve Almayan Hastalarda Preoperatif PET-BT’nin Tanısal Performansının Karşılaştırılması: ‹ndüksiyon Tedavisi Preoperatif PET-BT Sonuçlarını Etkiliyor mu?. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 23 - Sayı: 3, 143–152. https://ajindex.com/articles/323307

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Cerfolio RJ, Bryant AS, Ojha B. Restaging patients with N2 (stage IIIa) non-small cell lung cancer after neoadjuvant chemoradiotherapy: A prospective study. J Thorac Cardiovasc Surg 131: 1229-1235, 2006
  2. Eschmann SM, Friedel G, Paulsen F, et al. Repeat 18F-FDG PET-CT for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer. Lung Cancer 55: 165-171, 2007
  3. Hellwig D, Graeter TP, Ukena D, et al. Value of F-18- fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma. J Thorac Cardiovasc Surg 128: 892- 899, 2004
  4. Eschmann SM, Friedel G, Paulsen F, et al. 18F-FDG PET-CT for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer. Eur J Nucl Med Mol Imaging 34: 463-471, 2007
  5. Cerfolio RJ, Ojha B, Bryant AS, et al. The accuracy of integrated PET-CT compared with dedicated PET-CT alone for the staging of patients with non-small cell lung cancer. Ann Thorac Surg 78: 1017-1023, 2004
  6. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 111: 1710-1717, 1997
  7. Abea K, Baba S, Kanekoa K, et al. Diagnostic and prognostic values of FDG-PET-CT in patients with non-small cell lung cancer. Clinical Imaging 33: 90-95, 2009
  8. Subedi N, Scarsbrook A, Darby M, et al. The clinical impact of integrated FDG PET-CT on management decisions in patients with lung cancer. Lung Cancer 64: 301-307, 2009
  9. Yanga W, Fub Z, Yuc J, et al. Value of PET-BT/CT versus enhanced CT for locoregional lymph nodes in nonsmall cell lung cancer. Lung Cancer 61: 35-43, 2008
  10. Franzius C. FDG PET: advantages for staging the mediastinum? Lung Cancer 45 (Suppl 2): S69-S74, 2004
  11. Reed CE, Harpole DH, Posther KE, et al. American College of Surgeons Oncology Group Z0050 trial. Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non–small cell lung cancer. J Thorac Cardiovasc Surg 126: 1943- 1951, 2003
  12. Passlick B. Mediastinal staging (take home messages). Lung Cancer 45 (Suppl 2): S85-S87, 2004
  13. Cerfolio RJ, Ojha B, Bryant AS, et al. The Role of FDGPET scan in staging patients with nonsmall cell carcinoma. Ann Thorac Surg 76: 861-866, 2003
  14. Graeter TP, Hellwig D, Hoffmann K, et al. Mediastinal lymph node staging in suspected lung cancer: comparison of positron emission t